Nanoscaffolds for guided cardiac repair: the new therapeutic challenge of regenerative medicine by L. Ventrelli et al.
Hindawi Publishing Corporation
Journal of Nanomaterials
Volume 2013, Article ID 108485, 16 pages
http://dx.doi.org/10.1155/2013/108485
Review Article
Nanoscaffolds for Guided Cardiac Repair: The New Therapeutic
Challenge of Regenerative Medicine
Letizia Ventrelli,1,2 Leonardo Ricotti,2 Arianna Menciassi,2
Barbara Mazzolai,1 and Virgilio Mattoli1
1 Center for Micro-BioRobotics @SSSA, Istituto Italiano di Tecnologia, Viale Rinaldo Piaggio 34, 56025 Pontedera, Italy
2The BioRobotics Institute, Scuola Superiore Sant’Anna, Polo Sant’Anna Valdera, Viale Rinaldo Piaggio 34, 56025 Pontedera, Italy
Correspondence should be addressed to Letizia Ventrelli; l.ventrelli@sssup.it
Received 15 March 2013; Accepted 12 May 2013
Academic Editor: Mohamed Bououdina
Copyright © 2013 Letizia Ventrelli et al.This is an open access article distributed under the Creative CommonsAttribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cardiovascular diseases represent the leading cause of death and disability in the world. At the end-stage of heart failure, heart
transplantation remains the ultimate option. Therefore, due to the numerous drawbacks associated with this procedure, new
alternative strategies to repair the wounded heart are required. Cell therapy is a potential option to regenerate functionalmyocardial
tissue. The characteristics of the ideal cardiac cell therapy include the use of the proper cell type and delivery methods as well as
the choice of a suitable biomaterial acting as a cellular vehicle. Since traditional delivery methods are characterized by several
counter backs, among which low cell survival, new engineered micro- and nanostructured materials are today extensively studied
to provide a good cardiac therapy. In this review, we report the most recent achievements in the field of cell therapy for myocardial
infarction treatment and heart regeneration, focusing on the most commonly used cell sources, the traditional approaches used to
deliver cells at the damaged site, and a series of novel technologies based on recent advancements of bioengineering, highlighting
the tremendous potential that nanoscaffolds have in this framework.
1. Introduction
According to the World Health Organization (WHO), car-
diovascular diseases (CVDs) represent the leading causes of
death anddisability in theworld. Ischemic heart diseases such
as myocardial infarction (MI), in particular, represent widely
spread pathologies, producing significant morbidity [1]. MI
is characterized by a decrease of blood supply to the cardiac
tissue with a consequent death of cardiomyocytes and loss of
contractile function. As a further consequence, the resulting
nonfunctional tissue, which is still subjected to mechanical
loads, generates abnormal stresses at the infarct and peri-
infarct zone, with an expansion of the left ventricle [2]. The
mechanical and biological stresses imply continuous changes
at the structural, mechanical, and molecular levels, known
as postinfarct left ventricle remodeling [3] (Figure 1). This
process is highly dynamic and time dependent, comprising
(i) an acute inflammatory phase, evolving to (ii) a granulation
stage and then to (iii) chronic fibrosis. This degeneration
progress often culminates in heart failure and death.
At the end-stage of heart failure, heart transplantation
remains the ultimate option. However, the procedure of
replacing the failed heart with a healthy one raises several
limitations such as lack of organ donors, immune rejection,
and many other complications. Because of these restrictions,
researchers are still looking for new alternative strategies
to repair the wounded heart and permanently restore its
function. Among all approaches, cell therapy is a potential
option to regenerate functional myocardial tissue. Stem or
nonstem cell-based procedures are of great interest at present,
and they hold great promises for a significant recovery of
cardiac function. As known, the therapeutic effect of exoge-
nous stem cells is due to four main general mechanisms:
(i) differentiation of the administered cells into the cellular
constituents of the regenerating myocardium; (ii) release of
factors capable of paracrine signaling (a form of cell signaling
in which the targeted cell is close to the signal-releasing one)
from the administered cells; (iii) fusion of the administered
cells with the existing constituents of the target organ; (iv)
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Figure 1: Ventricular dilation associated with progressive heart failure. After the initial insult, infarct expansion and ventricular wall
thinning contribute to further ventricular remodeling, ultimately causing increased intraventricular pressure and decreased cardiac output.
Reproduced with permission of Elsevier.
restoration of endogenous stem cell niches in the target organ,
stimulated by exogenous cell delivery [4]. However, nonstem
cells have been also used for therapeutic purposes, such as
autologous or heterologous myoblasts.
The characteristics of the ideal “cardiac-therapeutic” cell
type include quantitative and temporal availability, safety of
administration, effectiveness of its engraftment, differentia-
tion ability, and (most importantly) cardiac repair capability
[5]. However, cell activity is not the only concern within this
picture; delivery methods and properly engineered bioma-
terials actually represent other two key aspects to consider.
As discussed in Section 3, all traditional delivery methods
lead towards low cell survival and/or limited therapeutic
efficacy [6]. Conversely, engineered micro- and nanostruc-
tured materials are widely studied at present to permit a
suitable cell differentiation and integration with the host
tissue as well as to release active compounds or to directly
or indirectly perform physical therapy. Cells in general and
stem cells in particular are strongly affected by extracellular
stimuli, such as soluble and adhesive factors, which bind to
cell-surface receptors. However, mechanical properties of the
extracellular matrix, especially rigidity, also play a key role in
cell signaling, proliferation, differentiation, andmigration [7,
8]. Similarly, topography is able to trigger specific behaviors
and/or to inhibit certain pathways [9]. The development of
properly engineered substrates mimicking natural stem cell
environment is therefore a crucial research field. In addition,
new active materials and highly technological integrated
devices are emerging, with the aim of providing injured heart
with locally delivered drugs and indirect or direct physical
stimulation [10–13]. Despite such synergistic joint efforts of
engineers, biologists, and material scientists, a number of
scientific and technological issues remain to be addressed
and solved before fully exploiting the potential of cell-based
regenerative therapies for heart-related pathologies. This will
be probably possible in a near future by means of even more
pronounced interdisciplinary research efforts [14].
This review aims to report the most recent achievements
in the field of cell therapy for MI treatment and heart
regeneration and to highlight the tremendous potential that
nanoscaffolds have within this challenge. Firstly, the most
common cell sources used in the last decades for cardiac
repair will be described showing also the most recent clinical
studies on humans. Then, the traditional approaches used to
deliver cells at the damaged site will be reported, discussing
their safety and their efficacy in inducing cardiac remod-
eling and healing. A series of novel technologies, based on
recent advancements of bioengineering will be then exposed,
including patches, fragments, active scaffolds, composite bio-
materials, and so forth. Finally, an original strategy for cardiac
repair based on magnetic nanosheets will be highlighted and
discussed, before drawing conclusions about the promises
of these new systems in the therapeutic challenge of heart
regeneration.
2. Sources of Cells for Cardiac Remodeling
Different cell sources and types determine different thera-
peutic outcomes. Cell-based treatment of cardiac pathologies
can be carried out by using either stem or nonstem cell
types. Concerning stem cells, their level of commitment
is strongly related to the therapeutic potential but also to
possible drawbacks, such as teratoma formation [15]. Based
on the differentiating potential, stem cells can be classified
into three categories. Pluripotent stem cells, such as induced
pluripotent stem cells (iPSCs) and human embryonic stem
cells (hESCs), show the greater healing potential thanks to
their ability to differentiate into cells of all three embryonal
layers (ectodermal, endodermal, and mesodermal). Multi-
potent stem cells, such as mesenchymal stem cells (MSCs),
can generate many cell types (e.g., muscle cells, hepatocytes,
blood cells, etc.) within a specific organ. Finally, oligopotent
stem cells (such as myeloid or lymphoid precursors) can
generate only few cell types (e.g., monocytes, macrophages,
etc.), and they are generally not taken into consideration for
cardiac repair.
Consistent differences can be also found between stem
cells of the same type but deriving from different sources. For
example, a comparative analysis between MSCs of different
origin revealed that those deriving from umbilical cord blood
show a limited isolation success rate and are not able to
differentiate in adipose tissue; however, they can be cultured
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for long periods and show a high proliferation capacity. On
the contrary, MSCs from bone marrow show high isolation
success rate and good differentiation capacity but very low
proliferation ability. Finally, MSCs from adipose tissue show
the highest colony frequency and good differentiation ability
[16].
hESCs and iPSCs have not been used in clinical studies
yet for the treatment of myocardial disease, due to a lack of
knowledge about their tendency to form tumor tissues when
used in vivo and to strong ethical issues related to the use
of human embryos (concerning hESCs) and to epigenetic
memory and other partly unknown phenomena related to the
use of iPSCs. However, the therapeutic potential of these cells
have been evidenced by many studies both in vitro [17–20]
and in vivo [21, 22], which highlighted the possibility of effi-
ciently differentiating pluripotent cells into cardiomyocytes
and, in general, of triggering cardiac regeneration.
Adult MSCs showed good promises not for their capa-
bility of directly differentiating into cardiac-like tissue, but
rather for their ability to induce “trophic effects” [23]. These
effects include secretion of cytokines and growth factors,
inhibition of fibrosis (and therefore prevention of scar for-
mation) and apoptosis, angiogenesis enhancement, and stim-
ulation of tissue-intrinsic reparative processes. Encouraging
results were obtained by using adipose tissue-deriving MSCs
in rat myocardial infarct models [24] and bone marrow-
derived MSCs in pig with damaged myocardium [25]. Con-
cerning MSC application to humans, the outcomes obtained
in eighteen clinical studies in which bone marrow-derived
cells (BMCs) were used for cardiac repair were reviewed and
meta-analyzed in 2007 [26].The results highlighted that BMC
transplantation is associated with modest improvements in
physiologic and anatomic parameters in patients with both
acute myocardial infarction and chronic ischemic heart
disease. However, research is still focused on the translation
of MSCs to the clinics by focusing on specific heart defects or
impairments [27].
Cardiac progenitor cells (CPCs) have been studied in
postnatal hearts, and specific surface markers expressed by
these cells have been identified. The most studied are the
CPCs expressing the tyrosine kinase receptor c-KIT [28].
Endogenous c-KIT+ cells (such as interstitial cells of Cajal,
thymic epithelium cells, and mast cells) are therefore under
study, in order to identify their regeneration potential. CPCs
from adult myocardium have been already reported to give
rise to cardiomyocytes in vitro and in vivo after transplan-
tation and to enhance cardiac function after infarction [29].
The “stemness” of CPCs has recently been questioned, and it
has been suggested that they are principally cardiac fibrob-
lasts, while CPC-derived cardiomyocytes are contaminants
derived from the original tissue [30].
Concerning other cells used for cardiac repair, the lit-
erature reports heterologous epicardium-derived cells [31],
skeletal myoblasts derived from skeletal muscle satellite cells
[32–34], fetal cardiomyocytes [35], fibroblasts, and smooth
muscle cells [36, 37]. In all these cases, even if some beneficial
effects were found to the infarcted heart (mainly due to
paracrine effects), the overall regeneration outcomes were
rather poor.
Another interesting possibility has been recently high-
lighted by Song and colleagues [38], who reprogrammed
cardiac fibroblasts into myocardial cells by using cardiac
transcription factors (GATA4, HAND2, MEF2C, and TBX5)
in mice.
In general, many years of in vitro and in vivo experiments
and clinical trials have permitted to draw some conclusions
[39]. Cell therapy is overall safe, with the caveat of ventric-
ular arrhythmias which still require careful scrutinization;
the cell type needs to be tailored to the primary clinical
indication, whereas the paracrine effects of bone marrow
cells may be therapeutically efficacious for limitation of
remodeling or relief of angina. Only cells endowedwith a true
cardiomyogenic differentiation potential are likely to affect
regeneration of chronic scars; autologous cells are primarily
limited by their variable and unpredictable functionality,
thereby calling attention to banked, consistent, and readily
available allogeneic cell products. Regardless of the cell type,
a meaningful and sustained therapeutic benefit is unlikely to
occur until cell transfer and survival techniques are improved
to allow greater engraftment rates. Furthermore, trial end
points probably need to be reassessed to focus onmechanistic
issues or hard end points depending on whether new or
already extensively used cells are investigated.
3. Traditional Approaches for the Delivery of
Cells in the Injured Heart
In addition to the cell type to be transplanted, another
key factor concerns the adoption of an efficient method
for cell delivery. The main objectives are (i) to ensure a
safe transplantation, (ii) to transplant a sufficient amount
of cells into the cardiac region of interest, (iii) to obtain
maximum retention of cells within the target area, and (iv) a
sufficient local engraftment [40]. Although there is a number
of available options to direct cells to the heart, in this section,
we focus on three basic strategies, namely, systemic therapy,
focused coronary infusion and direct myocardial injection.
3.1. Systemic Therapy. Systemic administration of cells can
be achieved through both growth factors mobilization and
peripheral venous injection [40].
In the growth factor treatment [41], myocardial regen-
eration via stem cells mobilization and migration from
tissues to injured myocardium is favoured by using specific
growth factors like stromal cell-derived factor-1 (SDF-1) and
stem cell factor (SCF). In particular, when the natural cell
processes are not sufficient for MI healing, these phenomena
are artificially induced and accelerated by supra doses of
such chemical agents. Askari et al. [42] investigated the
expression of SDF-1 by the myocardium after MI, finding a
significant upregulation immediately after infarction and a
downregulationwithin 7 days; the results suggested that SDF-
1 is sufficient to induce therapeutic stem-cell homing to MI.
Finally, though some findings showed general enhancement
of cardiac performance per se, the efficacy of the growth factor
therapy is improved when the treatment is combined with
standard cellular transplantation [43].
4 Journal of Nanomaterials
Compared with invasive delivery methods such as direct
intramyocardial injection, intravenous (IV) injection of cells
[44, 45] is the simplest and noninvasive delivery strategy to
treat myocardial diseases in humans. Moreover, the admin-
istration of a large numbers of cells can be easily repeated.
Peripheral infusion of stem cells (by the jugular vein, the
femoral vein, the scalp vein, etc.) is also used in small
animal (e.g., rats) and porcine models of MI showing limited
myocardial infarct size, reduced remodeling, and improve-
ment of cardiac function [46–48]. However, entrapment of
cells to noncardiac organs such as the lungs [45], lowering
the selectivity and efficiency of this approach, limits its
applicability.
3.2. Intracoronary Infusion. Selective intracoronary infusion
of cells in the proximity of ischemic myocardial areas allows
the delivery of a higher cell concentration in comparisonwith
systemic therapies. Successful experimental [49] and clinical
[50] studies have recently showed that BMCs and MSCs
delivered by the intracoronary route regenerated damaged
myocardium in acute MI. Chen at al. [51] investigated the
efficacy of intracoronary injection of BMCs in patient with
acute MI, confirming significant improvement on cardiac
function and on left ventricle remodeling. The infusion of
cells to the injured myocardium carried out in these studies
is technically simple to perform: cells are injected through
the central lumen of an over-the-wire balloon catheter during
transient balloon inflations in order to maximize the expo-
sure time of cells with the microcirculation of the infarct-
related vessel. Moreover, clinical trials also demonstrated the
feasibility, safety, and efficacy of this method [52]. However,
possible drawbacks may be the nonselective distribution of
the injected cells and, depending on the delivered cell type,
their ability to migrate from coronary vessels and to infiltrate
into the infarcted site without causing obstruction.
3.3. Direct Intramyocardial Injection. Direct myocardial inje-
ction is suitable to deliver cells in patients with chronic
myocardial diseases, such as chronic ischemia [53], or other
advanced coronary artery diseases [54], but it could be also
used to treat acute MI. Direct injection can be realized
transepicardially, transendocardially, or via the coronary
venous system [40].
Transepicardial cell injection can be performed during
open heart surgery, allowing for a direct visualization of
the myocardium. Due to its invasiveness, this technique
is commonly used in animal studies, whereas its clinical
application is limited to patients undergoing sternotomy for
different cardiac surgery. Menasche´ et al. [55] transplanted
autologous skeletal myoblasts in patients undergoing coro-
nary artery bypass grafting operations via multiple epicardial
echo-guided needle injections. Even if this first clinical trial
failed and no improvements in regional or global LV function
were found, the increased number of early postoperative
arrhythmic events after cell injection and LV remodeling for
high-dose injection laid the groundwork for future investiga-
tions.
Another possible strategy for direct cell injection is the
less invasive transendocardial delivery via a percutaneous
catheter-based approach [56]. To date, a multiplicity of
catheter systems are available for transendocardial injection
such as the Stiletto [57] or MyoStar [58] catheters. Basically,
all these systems are made up of multicomponent catheters
consisting of an injection needle for cell delivery and a
support catheter to direct the needle to the desired site.
Therefore, by passing the catheter retrogradely across the
aortic valve, it is placed against the endocardial surface,
thus allowing intramyocardial cell injection into the left
ventricular (LV) wall. Moreover, some of the catheter systems
described before integrate additional navigation capability
to facilitate the selection of target areas. Perin et al. [59]
performed an electromechanical mapping (EMM) of the
endocardial surface by integrating the MyoStar catheter with
the NOGA system; this study demonstrated the safety of
intramyocardial injection of bone marrow-derived stem cells
in patients with severe LV dysfunction and an improvement
in both perfusion and myocardial contractility.
The last emerging technique for direct cell repopulation
is transcoronary vein injection. In this approach, cells can
be intramyocardially injected through the coronary veins by
using a catheter placed inside the coronary vein itself. In
particular, Thompson et al. [60] reported a study in which
the coronary venous system of pigs was used as a road
map for direct cell injection. For this purpose, a special
catheter system incorporating an intravascular phased array
ultrasound tip for guidance and a preshaped extendable
nitinol needle for transvascular myocardial access were used.
While they demonstrated the feasibility (e.g., the widespread
intramyocardial access from the anterior interventricular
coronary vein) and safety (e.g., no death, no ventricular
arrhythmia, or other procedural complications) of percuta-
neous intramyocardial access, the efficiency of cell grafting or
functional properties of the myocardium after the injection
were not assessed. Nevertheless, the study carried out by
Thompson is an important step regarding the treatment of
myocardium via the coronary venous system.
In contrast to peripheral venous injection and intracoro-
nary infusion, where the specificity of the delivery is very low,
direct intramyocardial injection of cells represents a more
attractive route. This is due to the specific regions of the
myocardium that can be targeted (noncardiac entrapment of
the cells is reduced) and, as a consequence, to a highest local
tissue concentration that can be reached.
Finally, based on both the advantages and drawbacks
of the delivery methods previously reported, it is possible
to conclude that the choice of the more suitable strategy
depends on several factors, such as the specific disease the
patient is affected by and the type of cells to be transplanted.
For this reason, and as a consequence of the fast and
sophisticated technological improvements we are witnessing,
further studies and more clinical trials should be performed
in the near future.
4. New Approaches: Cell Sheet Engineering,
Fragments, and Patches
This section aims to report tissue engineering technolo-
gies recently developed for the treatment of MI. The most
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Figure 2: Cell sheet detachment from temperature-responsive cul-
ture surfaces. (a) ECM assures cell attachment to hydrophobic sur-
faces, and cell-to-cell junction proteins keep cells packed together;
(b) enzymatic digestion causes ECM, and junctions are disrupted,
and cells are released separately; (c) thermoresponsive culture
surfaces allow the release of cell sheets by lowering temperature.
Reproduced with permission of Wiley & Sons.
important features of these techniques are summarized in
Table 1.
In the nineties, Okano’s group developed an innovative
tissue engineering method named “cell sheet technology”
[61, 62]. Such technology is based on thermoresponsive
culture dishes designed by using a temperature-responsive
polymer, poly(N-isopropylacrylamide) (PNIPAAm), cova-
lently immobilized onto common tissue culture polystyrene
surfaces (TCPSs). By controlling the hydrophobicity of the
dish through temperature, it is possible to switch on and off
cell adhesion (Figure 2).
Through this method the seeded cells detach sponta-
neously and can be harvested in a noninvasive way as an
intact sheet together with their deposited extracellularmatrix
(ECM). In comparison with conventional tissue engineering
methodologies, cell sheet engineering shows several advan-
tages. Firstly, there is the possibility to harvest cells as
an entire sheet without using proteolytic enzymes such as
trypsin, which causes the breaking of adhesive proteins and
membrane receptors; furthermore, the presence of ECM on
the sheet allows the sheet to be directly transplanted into host
tissues without any mediators. Another important point is
the elimination of biodegradable scaffolds, thus reducing the
inflammatory response after implantation. Finally, the ability
to harvest cell sheets as both single layers and multilayers
(thus creating three-dimensional structures) paves the way to
advanced regenerative therapies, not only for the treatment
of MI. As regards myocardial reconstruction, cell sheets
obtained from PNIPAAm-grafted TCPS have been used with
different sources of cells [61, 63–66] and with cardiomyocyte
sheets layered in different numbers (from two up to four).
In vitro histological analyses showed an integration of the
single sheets, resulting in a homogeneous, continuous, and
cell-dense structure; moreover, thanks to the formation of
gap junctions after the layering, electrically synchronized cell
pulses were observed. In vivo, spontaneous beatings were
macroscopically noticed, and typical heart-like structures
were found out.
Sung’s group proposed an alternative approach, relying on
the same philosophy of cell sheet engineering [67–69]. A con-
tinuous cell sheet was harvested by using a thermoresponsive
methylcellulose (MC) hydrogel coated on TCPS dishes; then,
fragmented cell sheets were obtained by means of a stainless
screen. Finally, the collected fragments were transplanted by
injection through a needle (Figure 3).
In these studies, different cell types were used. Chen et al.
[67] and Wang et al. [68] reported fragmented sheets of rat
bone marrow MSCs, transplanted via intramyocardial injec-
tion directly into the periinfarct area using a needle. After
sheet preparation, both studies confirmed the preservation
of endogenous ECM; subsequent to injection, the MSC sheet
fragments showed the maintenance of their activity. In com-
parison with traditional delivery methods, a higher number
of MSCs were retained in the interested area, thus resulting
in a higher heart recovery. In a more recent work, Yeh et al.
[69] used human amniotic fluid stem cells (hAFSCs), known
to have angiogenic capability and cardiomyogenic potential.
After hAFSC isolation and expansion, cell sheet fragments
were prepared and transplanted into the peri-ischemic area of
a rat model. Again, the fragments preserved the endogenous
ECM, thus leading to enhanced cell retention in the area of
interest, and significant improvements in the cardiac function
were also observed.
Cardiac patches represent another interesting approach
for the treatment of heart pathologies [70–73]. Although
heart patches can be developed in different ways, they are
basically developed starting from both biological and syn-
thetic scaffolds laden with cells. Figure 4 shows an example
of cardiac patch.
Therefore, the two most important features being addre-
ssed during the development of cardiac patches are (i) the
choice of biomaterials to be used as scaffolds (showing
suitable mechanical properties, such as sufficiently strength
to resist the movement of myocardial tissue, adjustable
biodegradation times, and ability to both carry and preserve
cells) and (ii) the choice of proper cell sources for myocar-
dial repair. Based on these assumptions, several studies
can be found in the literature. Piao et al. [70] used rat
bone marrow-derived mononuclear cells (BMMNCs) seeded
onto a poly-glycolide-co-caprolactone (PGCL) scaffold; its
implantation into the epicardial surface of a rat MI model
producedmigration and differentiation of these cells towards
cardiomyocyte-related phenotypes. Chen et al. [73] also
fabricated a hybrid heart patch, demonstrating its capability
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Figure 3: Representation of cell sheet fragments preparation and suspension. Cells cultured on a thermoresponsive hydrogel (a) are allowed
to reach confluence and then fragmented bymeans of a stainless screen (b). Fragments are detached (c), suspended, and collected in a syringe
(d) to be injected in the host organ.
Multilayered MSCs Sliced biological scaffold Scaffold inserted with
multilayered MSCs
Implanted MSC patch Resection of infarcted myocardium
Myocardial repair with MSC patch
MSC patch
In vitro
culture
+
Figure 4: Scheme of preparation of a MSC-based therapeutic cardiac patch. Reproduced with permission of Elsevier.
to sustain cell viability and attachment as well as active cell
beating for long periods; moreover, in vivo tests showed
that the implanted patch remained undamaged over two
weeks without affecting ventricular function. In this case, the
cardiac patch was fabricated using again a synthetic scaffold
made of poly(glycerol sebacate) (PGS), seeded with different
cell types. In addition to synthetic scaffolds, biologicalmateri-
als can also be used to fabricate cardiac patches.Wei et al. [71]
and Huang et al. [72] used sliced porous biological scaffolds
(e.g., acellular bovine pericardia) and thermoresponsive MC
hydrogels coated on TCPS dishes and seeded with rat bone
marrowMSCs andmurineESCs, respectively. In both studies,
in vitro tests showed high cell viability and adhesion, whereas
a good integration into the host and an improvement of heart
functions were observed during in vivo test.
Since all these bioengineering-based components have to
be implanted into the human body, their future clinical appli-
cations will firstly require an eligible candidate and proven
safety of both cell sources and biomaterials. A good outline
of several newly developed tissue engineering techniques for
the treatment of heart diseases is reported in [74].
A deep inside analysis of both traditional methods of cell
delivery and the new bioengineering-based ones highlight
that, despite the direct cell injection should be an inefficient
route of delivery because of a high loss or death (more than
90% [75]) of cells, the combination of these approaches could
prevent cell loss augmenting the cell transfer efficiency and
giving a site-directed repair.
Finally, special attention has to be paid to biomaterials
because, if the cell sheet engineering avoids the use of
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Table 2: Advantages and disadvantages of novel tissue engineering technologies for the treatment of heart diseases.
Approach Advantages Disadvantages
Cell sheet
engineering
(i) Elimination of the use of biodegradable scaffolds, increased
cell-to-cell connections, and reduced inflammatory responses
(ii) Noninvasive cells harvesting as intact monolayer sheets: cultured
cells detach spontaneously by lowering temperature, thus avoiding
the use of proteolytic enzymes
(iii) Harvested cell sheets can be easily transferred and directly
attached to the host tissue
(iv) Ability to layer the harvested cell sheets: rapid cell-to-cell
connections between the layers
(i) Transplantation of cell sheets alone cannot
provide the proper mechanical strength
necessary for replacing the infarcted
myocardium
(ii) Need to rely on open surgery
Cell sheet fragments
(i) No use of proteolytic enzymes when harvesting cells
(ii) Injectable without open surgical methods
(iii) Good ability on cell attachment and proliferation when
transferred to other surfaces
(iv) High cell retention in the infarcted myocardium
(i) Lack of a controlled delivery inside vessels
(ii) Risk of thrombosis inside vessels
Bioengineered
cardiac patches
(i) Integration of the advantages of tissue-engineered scaffolds and
cell sheets
(ii) Ability to provide the required mechanical strength to support
seeded cell sheet systems
(iii) Prevention of cell loss to augment cell transfer efficiency, thus
allowing a site-directed repair
(i) Immunogenicity caused by residual
degraded scaffolds
(ii) Invasive open chest surgery
(iii) Materials should be optimized according
to the cell source
biodegradable scaffolds reducing inflammatory responses,
they are used to develop cardiac patches involving the
choice of the more suitable material up to the cell source.
Table 2 aims at resuming an exhaustive overview of the main
advantages and disadvantages of the above described novel
tissue engineering technologies.
5. Advanced Biomaterials for
Heart-Related Applications
As mentioned, the achievement of effective MI treatments
depends not only on the choice of themost suitable cell source
but also on the employed biomaterials. Since a biomaterial,
especially if used for clinical trials, interacts with biological
structures, the following main requirements are demanded
[76]: (i) biocompatibility with human body in general and
cardiac tissues in particular; (ii) safe biodegradability; (iii)
specific mechanical properties resembling those of the native
heart, such as strength and flexibility; and (iv) contraction
capability. An exhaustive list of biomaterials used in the last
decade forMI treatment is reported in Table 3, while Figure 5
shows, for some of them, their chemical structure, their
degradation times, and representative images of 2D or 3D
scaffolds.
The source of thematerial (i.e., natural, synthetic, or com-
posite-derived) marks several differences between its prop-
erties and possible applications [76–81]. Furthermore, its
delivery strategies should be also taken into account (i.e.,
injection, 3-D scaffolds, or patches) [77, 79, 81].
Concerning naturally derived materials, such as alginate,
chitosan, collagen, and fibrin are themost used ones. Alginate
is an anionic polysaccharide found in the cell walls of brown
seaweed and, thanks to its biocompatibility and gelation with
divalent cations (such as Ca++) of the myocardial tissue,
it shows good potential for MI treatment. Leor et al. [82]
prepared an alginate-calcium solution that was intracoronary
injected into a swine model of MI: the solution diffused
into the infarcted zone and replaced the damaged ECM,
thus preventing LV dilation. Chitosan is another linear
(cationic) polysaccharide. Because of its biocompatibility and
biodegradability, it is often used in biomedical applications
ranging from drug delivery to tissue engineering. Wang et al.
[83] intramyocardially injected a temperature-responsive
chitosan hydrogel provided with specific growth factors into
rat infarction models, obtaining significant improvements
in cardiac functions. Fibrin glue, a biomaterial made up of
fibrinogen and thrombin, can be also used for controlled
release of growth factors. Nie et al. [84] demonstrated an
enhancement in myocardial perfusion and cardiac func-
tions in a canine infarct model by means of fibrin glue
incorporating basic fibroblast growth factors. As described
previously, all these materials can be either injected or used
as delivery vehicles. An in-depth description of biological
materials (concerning structure and mechanical properties)
can be found in [85].
Syntheticmaterials represent another category of bioscaf-
folds used for heart regeneration. Widely used biodegradable
and biocompatible polymers are poly(lactic acid) (PLA),
poly(glycolic acid) (PGA), and their copolymers, for example,
poly(lactic-co-glycolic acid) (PLGA) [76, 77, 80]. Caspi et
al. [86] reported the achievement of an engineered human
cardiac tissue showing good contracting ability, thus demon-
strating the capability of developing a highly vascularized
tissue with specific cardiac structures and functions. The
3D biodegradable polymeric scaffold used in this study was
half made of PLGA and the other half of another widely
used polymer, poly(L-lactic acid) (PLLA). This substrate was
subsequently seeded with different cell culture combinations,
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Table 3: Biomaterials for MI treatment reported in literature, in the
last decade.
Biomaterial Deliverystrategies Reference
Naturally derived materials
Alginate Injectable [80]3D scaffold [76–79]
Chitosan Injectable [77]Patches [78, 79]
Collagen
Injectable [80]
3D scaffold [76]
Patches [77, 78]
Extracellular matrix Injectable [76]Patches [79]
Fibrin and fibrin glue Injectable [76]3D scaffold [77–79]
Gelatin Injectable [76, 77]
Silk fibroin Patches [77]
Synthetic materials
PEG Injectable [76]Films [78]
PLA 3D scaffold [76, 77, 80]
PGA 3D scaffold [76, 77, 80]
PLGA 3D scaffold [76, 77, 80]
PU 3D sheet [76, 77]
PEU 3D scaffold [77]
PEUU 3D scaffold [76]Patches [77]
TMC Films [76]
PTMC Films [77]
DLLA Films [76]
PNIPAAm Cell sheet [76]Injectable [78]
PGCL Patches [76]
PGS 3D scaffold [77]
PCL Patches [77]
Self-assembling peptides Injectable [78, 79]
Other synthetic hydrogels Injectable [79]
Composites materials
𝜀-Caprolactone-co-L-lactide
reinforced with PCLA, gelatin or
PGA
Patches [80]
PEUU with type I collagen 3D scaffold [76]
Poly(caprolactone) with type I
collagen 3D scaffold [76]
Decellularized materials
Urinary bladder matrix, SIS Injectable [78]
Porcine ventricular and pericardial
tissue Patches [78]
MTE: myocardial tissue engineering; 3D: three dimensional; PEG: poly
(ethylene glycol); PLA: poly(lactic acid); PGA: poly(glycolic acid); PLGA:
poly(lactic-co-glycolic acid); PU: polyurethane; PEU: polyester urethane;
PEUU: Poly(ester urethane) urea; TMC: 1,3-trimethylene carbonate; PTMC:
poly(1,3-trimethylene carbonate); DLLA: D,L-lactide; PNIPAAm: poly(N-
isopropylacrylamide); PGCL: poly-co-caprolactone; PGS: poly(glycerol
sebacate); PCL: poly(𝜀-caprolactone); PCLA: poly(L-lactide); SIS: small
intestine submucosa.
each one based on the use of hESCs; by adding endothelial
cells (ECs) and embryonic fibroblasts (EmFs), vascularization
was finally encouraged. Such triculture system (composed of
fibroblasts, endothelial cells, and cardiomyocytes) was also
reported by Iyer and Radisic [76, 87], who used poly(ethylene
glycol) (PEG) scaffolds as substrates for cell seeding.
Poly(𝜀-caprolactone) (PCL) [76, 77] is a biodegradable
polyester which is degraded, in physiological conditions,
by hydrolysis of its ester linkages; for this reason, it has
been approved by the Food and Drug Administration (FDA)
and, today, is widely used in several biomedical applications.
PCL is often copolymerized with glycolide, resulting in
poly(glycolide-co-caprolactone) (PGCL). Piao et al. [70, 76]
fabricated cardiac patches made of PGCL and seeded them
with BMMNCs; therefore, implants in rat MI models were
performed, and a reduced LV remodeling and systolic dys-
function were achieved.
A recently developed biodegradable material for soft
tissue engineering purposes is a special elastomer, named
poly(glycerol sebacate) (PGS) [73, 77].Thanks to its mechan-
ical properties, comparable to those of the heart tissue, it has
been used as cardiac patch by Chen et al. as previously men-
tioned [73]. Finally, another interesting synthetic material
is poly(N-isopropylacrylamide) (PNIPAAm), a temperature-
sensitive polymer that switches its surface properties from
hydrophobic to hydrophilic below physiological temperature.
As already mentioned, this property has been used for cell
sheet engineering approaches.
The combination of natural and syntheticmaterials allows
the preparation of composite scaffolds. Some examples are
represented by poly(ester urethane) urea (PEUU) blended
with type I collagen [76], and 𝜀-caprolactone-co-L-lactide
reinforced with poly(L-lactide) (PCLA), gelatin, or PGA [80]
(see Table 3).
Finally, decellularized materials (tissues and organs) have
been also used as bioscaffolds for tissue engineering and
regenerative medicine applications [71, 72, 78, 88]. Decel-
lularization consists of the removal (by means of physical,
chemical or enzymatic methods) of cells from a tissue or an
organ, maintaining only its ECM. Even if the native source
tissue/organ and the decellularization methods affect the
structure of the ECM scaffold and therefore its response
before and after the implantation in the body, this could
represent a good way to provide cells with the best environ-
ment in which they can grow, proliferate, migrate, and dif-
ferentiate. Furthermore, decellularization is helpful because
the removal of antigens could avoid inflammations and,
consequently, a transplant rejection. Singelyn and Christman
[78] reported some examples of decellularized materials
used for cardiac applications such as decellularized small
intestine submucosa (SIS), intact rat and porcine hearts, and
decellularized ventricular and pericardial ECM. In particular,
Christman’s group [78, 89] carried out in vitro and in vivo
studies on an injectable decellularized myocardial matrix,
made of porcine ventricular tissue, in order to characterize
its composition and structure. The experiments showed
the capability of myocardial matrix to gel both in vitro
and in vivo upon epicardial injection, to self-assemble in
nanofibrous scaffolds, and to promote both in vitro and in vivo
migration of endothelial and smooth muscle cells within the
structure.
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Figure 5: Biomaterials widely used for MI treatment. For each of them, the chemical structure (top), representative images of the scaffold
(middle) and the degradation time (bottom) are reported. Reproduced with permission of Elsevier and Wiley & Sons.
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Figure 6: Polymeric nanofilms. (a) Scheme of single and multilayer nanofilm fabrication process; (b) magnetic nanofilms: injection (top)
and ejection (bottom) sequence. Reproduced with permission of Elsevier, Springer, and Wiley & Sons.
6. Cells on Magnetic Nanosheets and
Their Guidance
In addition to the already described technologies, an original
approach based on polymeric nanofilms recently emerged,
and it holds great promises for the treatment of heart diseases.
Nanofilms are polymeric films showing a relatively large
area (∼100 cm2) and a nanometric thickness (10–100 nm),
which leads to define them as “quasi 2D structures”. Their
flexibility, associated with robustness and high biocompat-
ibility as well as the possibility to use numerous polymers
to fabricate them, opens the way to several applications in
the biomedical field, ranging from biochemical or physi-
cal sensors, drug delivery systems, or substrates for tissue
engineering [90, 91]. Concerning their fabrication, polymeric
nanofilms can be prepared both as single and multilayer
films by means of a simple method firstly proposed by
Takeoka’s group, namely, spin coated assisted deposition [90].
In Figure 6(a), a simple scheme of the spin coating process
is shown. This technique is used as a single or a multistep
process, according to the required number of layers [92–94].
Two different approaches are exploited in order to produce
ultrathin nanosheets [95, 96].The former uses awater-soluble
polymer as a sacrificial layer, which is directly spun onto a
substrate via spin coating; subsequently, another layer of the
desired polymer is deposited on top. In the latter, a polymeric
layer is firstly deposed onto the substrate, followed by the
spinning of the polymeric supporting layer.
Since one of the key purposes of ultrathin films concerns
their use as drug or cell carriers (as discussed below), the
handling, control, and positioning of nanofilms inside the
human body represent crucial requirements. A possibility
that recently emerged consists of the development of mag-
netic nanofilms, specifically nanosheets containing magnetic
elements. This feature allows an external and noninvasive
approach, based on the use of an outer magnetic field, which
can be adopted for an accurate displacement of the film
within the body. A recent study performed byMattoli’s group
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Table 4: Novel approach based on ultrathin nanofilms.
Authors Technology Methods Cell types Materials Possible applications Reference
Pensabene et al., 2009
Mattoli et al., 2009
Polymer
nanosheets
bearing magnetic
nanoparticles
Spin coating
method
(i) PVA
(ii) PLLA
(iii) NPs
Biomedical field as
free-standing carriers
or as plasters
[95, 96]
Ricotti et al., 2010
Polymer
nanosheets
bearing cells
Spin coating
method
C2C12 mouse
myoblast cell line
(i) PVA
(ii) PLA
(i) Regenerative
medicine
(ii) Muscle tissue
engineering
(iii) Drug delivery
[101]
Fujie et al., 2010
Polymer
nanosheets
bearing cells
Layer-by-layer
assembly method
NIH-3T3 mouse
fibroblast cell line
(i) COL
(ii) HA
(i) Regenerative
medicine
(ii) Cell biology
[97]
Fujie et al., 2011
Polymer
nanosheets
bearing cells
Spin coating
method
H9c2 embryonic
myocardium rat cell
line
(i) PVA
(ii) PLLA
Building of specific
cell culture
environments
[99]
PVA: poly(vinyl alcohol); PLLA: poly(L-lactic acid); NPs: iron oxide nanoparticles; PLA: poly(lactic acid); COL: collagen; HA: hyaluronic acid.
[96] was based on the fabrication of nanofilms functionalized
with paramagnetic nanoparticles (NPs).Themagnetic behav-
ior of the nanosheet, floating in water, was evaluated by using
an external permanent magnet (field intensity Br = 350mT):
results showed a fine film controllability and highlighted that
velocities were strictly correlated to the concentration of the
loaded NPs. A practical application of magnetic nanofilms
was described by Pensabene et al. [95]. In this work, magnetic
nanofilmswere developed and evaluated as both drug carriers
and nanoplasters. Magnetic nanosheet manipulation was
tested by using a micropipette (Figure 6(b)); adhesion to the
gastric mucosa was also assessed. Furthermore, the control
and positioning of the films in a liquid environment (water)
were finally addressed, showing their ability to reach and
attach on the tissue.These outcomes allowed to conclude that
the use of magnetic nanofilms constitutes a feasible strategy
for bringing and releasing in a controlled way drugs or cells
in different areas of the human body. Of course, further
studies will be required in order to assess both the proper
concentration of magnetic components and the appropriate
values of external magnetic fields.
As previously mentioned, free-standing polymeric ultra-
thin films can be also used as novel cell culture systems and
cell carriers, in order to be applied to several biomedical
applications (e.g., cell biology, tissue engineering and regen-
erative medicine applications, and included MI therapy).
The most recent studies focusing on the adhesion and
proliferation properties of cells seeded onto single layer or
multilayer nanofilms are summarized in Table 4.
In [97], Fujie et al. reported the fabrication of two types
(i.e., fibril and nonfibril) of free-standing ECM-like mul-
tilayer nanosheets made of biopolymers such as type I
collagen (COL) and hyaluronic acid (HA). Both layer-by-
layer (LbL) assembly method [98] and supporting tech-
nique [95, 96] were used. Subsequently, the morphological
and mechanical features of the ECM-like nanosheets as
well as their mechanical effects on the adhesive properties
of NIH-3T3 mouse fibroblasts seeded on it were studied.
Results showed that the elongation of cells increased on the
fibril-based nanofilms, whereas it decreased on the nonfibril-
based ones.This study demonstrated that cell adhesion prop-
erties were tuned by simply varying the structural ECM
components of the nanosheets (e.g., the content of HA and
COL fibrils). The mechanical effects of freely suspended
polymeric nanofilms on cell adhesion properties have been
also assessed by studying how nanosheet stiffness affects
biological responses. Fujie et al. [99] synthesized ultra-
thin films, composed of PLLA and showing different stiff-
nesses, obtained by changing their thickness; H9c2 cells (an
embryonic myocardium rat cell line) were then cultured
onto these substrates. The adhesion properties of H9c2 on
these nanofilms were valued by estimating adhesion area
and elongation ratio of cells, highlighting similar results to
previously reported ones [97]: cells preferentially adhered
on rigid substrates in comparison to soft ones. Pensabene
et al. [100] used single similar nanosheets to sustain human
mesenchymal stem cell adhesion, proliferation, and differen-
tiation, thus highlighting the possibility of using nanosheets
as smart carriers of therapeutic cells. Finally, another example
in which nanosheets were used as cell culture systems was
reported by Ricotti et al. [101]. Here, the development of free-
standing single layer PLA nanofilms as cellular scaffolds was
described. After their characterization in terms of thickness
and roughness, viability, adhesion, and proliferation proper-
ties of C2C12mousemyoblasts cultured onto these substrates
were assessed. Early differentiation was also verified.
In conclusion, cell adhesive properties can be tuned by
changing both the structural components and themechanical
properties of polymeric nanosheets. Furthermore, the use of
suitable biocompatible polymers as well as the choice of the
proper cell line should allow the development of novel ultra-
thin films acting like cell-based matrices to be transplanted
in human bodies for the treatment of several heart diseases
(such as MI). Such results also suggested the possibility of
using polymeric ultra-thin films as structural components for
the development of bio-hybrid actuators, opening different
and parallel applicative routes with respect to those related to
pure regenerative medicine [102].
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7. Conclusions
At present, researchers are looking for new alternative strate-
gies to repair the wounded heart and restore its function.
Among the several approaches pursued, cell-based treatment
is a promising option for cardiac pathologies. In this review,
we reported the most recent achievements in the field of
cell therapy for MI treatment and heart regeneration. The
most common cell sources used in the last decades for
cardiac repair and the traditional approaches employed to
delivery cells at the damaged site have been described. Then,
a series of novel technologies based on recent advance-
ments of bioengineering and tissue engineering have been
illustrated, including patches, fragments, and biomaterials.
Finally, an original strategy for cardiac repair based on
magnetic nanosheets has been discussed, highlighting the
tremendous potential and promises that nanoscaffolds have
within the therapeutic challenge related to heart regeneration.
On the basis of the findings reported in this last section,
the magnetic nanofilm-based approach looks really promis-
ing. This therapeutic philosophy implies that the injection
of cell-seeded nanosheets inside the body and its guidance
up to the damaged heart site can deeply improve MI ther-
apeutic outcomes. Furthermore, the possibility of loading
the nanofilm with specific growth factors or drugs makes
this new bioengineering approach even more appealing and
promising.
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